MedPath

use of resveratrol in periodontitis and diabetes

Phase 4
Completed
Conditions
Health Condition 1: K053- Chronic periodontitis
Registration Number
CTRI/2022/05/042806
Lead Sponsor
katamneni poojitha
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Patients with moderately controlled diabetes mellitus (HbA1c 6-7)

patients with generalized pocket depth of 5- 6 mm and CAL � 5mm.

Patients having atleast 20 permanent teeth.

Should not have undergone any form of dental treatment

Exclusion Criteria

1.Patients with any systemic disease other than diabetes.

2.Habit of smoking

3.Pregnancy or lactation

4.Used antibiotics /or anti- inflammatory drugs in the last 3 months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Periodontal therapy proved to be effective in reducing the inflammatory state and oxidative stress, as well as improving the glycemic control in diabetic patients. <br/ ><br> <br/ ><br> The present study is planned to observe the benefits of systemic administration of resveratrol in chronic periodontitis patients with type II diabetes before and after scaling and rootplaning. Parameters were recorded at baseline, 7 weeks postoperative. Primary outcome parameters assessed were HbA1C, Probing pocket depth (PPD) and Clinical attachment level (CAL).Timepoint: Baseline <br/ ><br>7 weeks post operative
Secondary Outcome Measures
NameTimeMethod
plaque index(PI), Modified sulcular bleeding index(MSBI) as secondary outcome parameters.Timepoint: Baseline <br/ ><br>7 weeks post operative
© Copyright 2025. All Rights Reserved by MedPath